Sweeney C, Gilsenan A, Calingaert B, Moeller C, Schomakers G, Sok A, Holzmann R, Pisa F. Physician awareness of the safe use of cyproterone acetate in Europe: a survey on the effectiveness of additional risk minimization measures. Pharmaceut Med. 2024 Mar;38(2):145-56. doi: 10.1007/s40290-023-00510-x.
Sweeney C, Calingaert B, Holzmann R, Moeller C, Schomakers G, Sok A, Pisa F, Gilsenan A. Physician knowledge of safe use of cyproterone acetate monotherapies and meningioma. Poster presented at the 39th ICPE Annual Conference; August 26, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):300. doi: 10.1002/pds.5687
Gilsenan AW, Midkiff KD, Andrews EB, Von Scheele BG, Masica D, Ceberg J. Multinational collaboration: a long-term surveillance program for osteosarcoma and potential exposure to teriparatide. Presented at the 36th meeting of the Scandinavian Sarcoma Group; October 2013.
Gilsenan AW, Norwood GJ, Hanson-Divers EC. NC versus ME Medicaid: rx to OTC switch of vaginal antifungals. Poster presented at the American Pharmaceutical Association National Meeting; 1995. Orlando, FL.
Gilsenan AW, Norwood GJ. Has there been a significant increase in the number of prescription-only vaginal antifungal products dispensed to NC Medicaid patients compared to a control state since over-the-counter products in the therapeutic category have become available? Presented at the Southern Pharmacy Administration Conference; 1994. Gainesville, FL.